Savage William Jacob 4

What Happened

• William Jacob Savage, Chief Medical Officer of Disc Medicine, sold a total of 5,731 shares (dispositions) in two open-market transactions on April 13, 2026, for aggregate proceeds of approximately $380,449.
  • 3,531 shares disposed at a weighted-average price of $66.12 (total ≈ $233,473).
  • 2,200 shares disposed at a weighted-average price of $66.81 (total ≈ $146,976).
• These were sales (not purchases); sales are often routine (e.g., planned sales, tax or diversification reasons) and do not by themselves indicate management’s view of the company’s prospects.

Key Details

• Transaction date: April 13, 2026; Form 4 filed April 15, 2026 (timely filing within the required reporting window).
• Prices/ranges:
  • 3,531 shares: reported weighted average $66.12; actual trade prices ranged $65.50–$66.39 (per footnote).
  • 2,200 shares: reported weighted average $66.81; actual trade prices ranged $66.57–$67.00 (per footnote).
• Total shares sold: 5,731; total proceeds: about $380,449.
• Shares owned after transaction: not specified in the information provided on the Form 4.
• Notable footnote: Transactions were executed under a Rule 10b5-1 trading plan adopted October 2, 2025 (pre-arranged plan). The filer also offers to provide detailed per-price quantities within the reported ranges upon request.

Context

• Sales under a 10b5-1 plan are pre-scheduled trades and are commonly used by insiders to avoid trading when in possession of material nonpublic information; they are generally considered routine rather than a direct signal of insider sentiment.
• For retail investors, purchases typically carry more weight as a bullish signal; routine sales like this should be viewed as part of an insider’s personal financial management unless accompanied by other substantive insider activity.